- Home
- UTHR
as 02-21-2025 4:00pm EST
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
Upcoming Earnings Alert:
Get ready for potential market movements as United Therapeutics Corporation UTHR prepares to release earnings report on 26 Feb 2025.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 16.1B | IPO Year: | 1999 |
| Target Price: | $382.08 | AVG Volume (30 days): | 377.3K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 22.72 | EPS Growth: | 25.10 |
| 52 Week Low/High: | $218.41 - $417.82 | Next Earning Date: | 02-26-2025 |
| Revenue: | $2,756,200,000 | Revenue Growth: | 25.04% |
| Revenue Growth (this year): | 26.1% | Revenue Growth (next year): | 10.43% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Feb 3 '25 | Sell | $351.97 | 9,300 | $3,286,275.68 | 1,800 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Jan 27 '25 | Sell | $371.38 | 9,700 | $3,594,760.71 | 1,800 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Jan 21 '25 | Sell | $365.12 | 9,655 | $3,522,014.38 | 1,800 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Jan 13 '25 | Sell | $364.18 | 9,300 | $3,388,689.01 | 1,800 | |
| PATUSKY CHRISTOPHER | UTHR | Director | Jan 10 '25 | Sell | $361.39 | 5,000 | $1,808,071.86 | 5,600 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Jan 6 '25 | Sell | $355.52 | 9,500 | $3,372,360.18 | 1,800 | |
| Mesa Nilda | UTHR | Director | Dec 30 '24 | Sell | $355.77 | 255 | $90,720.10 | 5,528 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 30 '24 | Sell | $356.45 | 9,500 | $3,387,711.25 | 1,800 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 23 '24 | Sell | $360.57 | 8,700 | $3,146,489.01 | 1,800 | |
| SULLIVAN LOUIS W | UTHR | Director | Dec 18 '24 | Sell | $374.38 | 26,209 | $9,781,714.72 | 20,580 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Business Wire
3 days ago
United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
StockStory
8 days ago
United Therapeutics (UTHR): Buy, Sell, or Hold Post Q3 Earnings?
Zacks
9 days ago
Strength Seen in United Therapeutics (UTHR): Can Its 4.9% Jump Turn into More Strength?
Zacks
9 days ago
Ardelyx (ARDX) Earnings Expected to Grow: Should You Buy?
Insider Monkey
10 days ago
United Therapeutics Corporation (UTHR): A Cheap Biotech Stock to Invest In Now
Argus Research
12 days ago
Weekly Stock List
Zacks
15 days ago
UTHR or ZTS: Which Is the Better Value Stock Right Now?
MT Newswires
16 days ago
UBS Adjusts Price Target on United Therapeutics to $460 From $475, Keeps Buy Rating
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.